Short Interest in Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Rises By 528.9%

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the recipient of a large increase in short interest in May. As of May 29th, there was short interest totaling 298,780 shares, an increase of 528.9% from the May 14th total of 47,507 shares. Based on an average daily volume of 667,164 shares, the short-interest ratio is presently 0.4 days. Approximately 0.0% of the company’s shares are sold short.

Daiichi Sankyo Stock Down 0.1%

Shares of DSNKY stock traded down $0.01 during trading on Friday, hitting $15.85. 147,140 shares of the company were exchanged, compared to its average volume of 429,090. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.85 and a current ratio of 2.69. The firm has a market capitalization of $30.03 billion, a price-to-earnings ratio of 16.86, a P/E/G ratio of 1.06 and a beta of -0.16. The business’s 50-day simple moving average is $16.94 and its 200 day simple moving average is $19.14. Daiichi Sankyo has a twelve month low of $14.98 and a twelve month high of $27.50.

Daiichi Sankyo (OTCMKTS:DSNKY) last posted its quarterly earnings results on Monday, May 11th. The company reported $0.15 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.18). The company had revenue of $3.76 billion for the quarter, compared to analyst estimates of $3.74 billion. Daiichi Sankyo had a return on equity of 15.74% and a net margin of 12.32%.Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. As a group, analysts forecast that Daiichi Sankyo will post 0.94 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Zacks Research upgraded shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research report on Tuesday, May 5th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Hold”.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.